Featured Research

from universities, journals, and other organizations

Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow

Date:
November 12, 2013
Source:
University of Michigan Health System
Summary:
Big name athletes have reportedly used PRP therapy for sports injuries. Does it work?

A procedure intended to help heal musculoskeletal injuries called platelet-rich plasma therapy, or P.R.P., has created a big buzz in sports medicine and the media in recent years. Tiger Woods reportedly received the procedure for a sore knee and Pittsburgh Steelers' Hines Ward used it for a sprained knee ligament just before playing a key role in the team's 2009 Super Bowl victory.

Related Articles


However, the method -- which involves concentrating the platelets in a patient's blood sample and re-injecting them into the injured area to boost the body's own healing powers -- is expensive and rarely covered by insurance because it lacks scientific research to back it up.

Researchers at the University of Michigan are taking a step towards answering some questions about the therapy through a new clinical trial exploring how PRP specifically affects tennis elbow (or lateral epicondylitis). People with this condition experience pain from injury and degeneration in the tendon along the outside of the elbow, especially with extending the wrist. It can be caused by overuse or sports related repetitive strain.

"The popularity of PRP has moved faster than the science," says principal investigator Jon Jacobson, M.D., U-M Musculoskeletal Division Director and Professor of Radiology in the U-M Medical School. "Tennis elbow can be a debilitating condition, and the goal of the study is determine whether symptoms are improved in people who receive PRP injections compared to those who receive alternative and much cheaper types of treatment."

Other treatments for tennis elbow, such as corticosteroid injection, have shown little long-term success.

Researchers will compare the effects of physical therapy alone versus physical therapy in conjunction with either dry needle tendon fenestration (needling the tendon to make it bleed and to induce healing), re-injection of a patient's venous blood, or re-injection of the concentrated platelet-rich layer of a patient's own blood (PRP). This trial is unique in that it is a blind study (which means participants don't know which arm of the study they're in, preventing false positive experiences based on the placebo effect) to specifically compare PRP outcomes to other forms of treatment.

"PRP injection has emerged as a treatment alternative for many musculoskeletal conditions and recently been popularized by the media because of its use among well-known athletes -- however it costs more than other options and success stories have yet to be properly grounded in science," Jacobson says.

"If we find that platelet rich plasma is better compared to the other treatments, it would justify the high cost and growing industry associated with the procedure."


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow." ScienceDaily. ScienceDaily, 12 November 2013. <www.sciencedaily.com/releases/2013/11/131112141239.htm>.
University of Michigan Health System. (2013, November 12). Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2013/11/131112141239.htm
University of Michigan Health System. "Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow." ScienceDaily. www.sciencedaily.com/releases/2013/11/131112141239.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins